journal article·2025-08-01Open access

Impact of Pre- and Post-Dilatation on Long-Term Outcomes After Self-Expanding and Balloon-Expandable TAVI

Alexandru Stan, Ayman Elkahlout, Marius Mihai Harpa, Marian Pop, Mihaly Veres, Antonela Delia Stan, Paul-Adrian Călburean, Anda-Cristina Scurtu, Klara Brînzaniuc, Horatiu Suciu

Abstract

The main objective of this study was to compare the long-term outcomes of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis, focusing on differences between self-expanding valve (SEV) versus balloon-expandable valve (BEV) prostheses and the influence of balloon pre- and post-dilatation on clinical results. The secondary objective was to report the long-term outcomes after TAVI in Romania. All patients who underwent a TAVI procedure for severe AS between November 2016 and May 2025 at a tertiary center in Romania were included in the present study. A total of 702 patients were included, of which 455 (64.8%) and 247 (35.1%) patients received a BEV (Sapien3 platform) and a SEV (Accurate, Boston, Portico, Evolut, or Navitor platforms), respectively. Pre-dilatation was performed in 514 (73.2%) cases, and post-dilatation was performed in 189 (26.9%) cases. There were 10.5 and 7.8 all-cause and cardiovascular-cause mortality event rates per 100 patient years, respectively. In regard to the univariable Cox regression, a BEV has significantly lower mortality than an SEV (HR = 0.67[0.46–0.96], p = 0.03), pre-dilatation did not influence mortality (HR = 0.71[0.48–1.04], p = 0.08), and post-dilatation significantly increased mortality (HR = 1.51[1.05–2.19], p = 0.03). In regard to the multivariable Cox regression, survival was not influenced by pre-dilatation or the valve platform, while post-dilatation had a trend towards higher mortality (p = 0.06). The BEV and SEV have similar survival rates, with no heterogeneity among a large number of TAVI platforms. While pre-dilatation had no impact on mortality, post-dilatation was associated with a trend towards increased mortality (p = 0.06), which was independent of the transprosthetic gradient. Survival after TAVI in Romania is comparable to that reported in Western registries.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cardiac Valve Diseases and Treatments · Infective Endocarditis Diagnosis and Management · Aortic Disease and Treatment Approaches

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Doctoral School, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureş, 540142 Târgu Mureş, Romania

Department of Interventional Cardiology, Emergency Institute for Cardiovascular Diseases and Transplantation, 540136 Târgu Mureș, Romania

Department of Surgery IV, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540142 Târgu Mureș, Romania

Department of Cardiovascular Surgery, Emergency Institute for Cardiovascular Diseases and Transplantation, 540136 Târgu Mureș, Romania

Department of Radiology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540142 Târgu Mureș, Romania

Department of Intensive Care, Emergency Institute for Cardiovascular Diseases and Transplantation, 540136 Târgu Mureș, Romania

Faculty of Law, University of Bucharest, 030018 Bucharest, Romania

Department of Biostatistics and Medical Informatics, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureş, 540142 Târgu Mureş, Romania

Department of Anatomy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540142 Târgu Mureș, Romania

References (32)

Show source-provided references
1. Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly10.1056/NEJM199907153410302 ↗
2. Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement10.1056/NEJMoa1200384 ↗
3. Pre-dilation and Post-dilation in Transcatheter Aortic Valve Replacement: Indications, Benefits and Risks10.15420/icr.2020.35 ↗
4. Wang, B., Mei, Z., Ge, X., Li, Y., Zhou, Q., Meng, X., and An, G. (2023). Comparison of outcomes of self-expanding versus balloon-expandable valves for transcatheter aortic valve replacement: A meta-analysis of randomized and propensity-matched studies. BMC Cardiovasc. Disord., 23.10.1186/s12872-023-03397-3 ↗
5. Outcomes of Transcatheter Aortic Valve Replacement Using Third-Generation Balloon-Expandable Versus Self-Expanding Valves: A Meta-analysis
6. Transcatheter Aortic Valve Implantation With or Without Predilation: A Meta-Analysis10.25270/jic/21.00023 ↗
7. Post-dilation in transcatheter aortic valve replacement: A systematic review and meta-analysis10.1111/joic.12378 ↗
8. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve10.1016/j.jcin.2012.02.010 ↗
9. Cardiovascular disease burden due to productivity losses in European Society of Cardiology countries
10. Economic burden of cardiovascular diseases in the European Union: A population-based cost study10.1093/eurheartj/ehad583 ↗
11. Harrell, F.E. (2015). Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, Springer International Publishing.10.1007/978-3-319-19425-7 ↗
12. The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinements10.1002/wics.1460 ↗
13. Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice10.1016/j.jclinepi.2022.01.011 ↗
14. Final 3-Year Outcomes of a Randomized Trial Comparing a Self-Expanding to a Balloon-Expandable Transcatheter Aortic Valve10.1161/CIRCINTERVENTIONS.123.012873 ↗
15. Aortic valve replacement vs. balloon-expandable and self-expandable transcatheter implantation: A network meta-analysis10.1016/j.ijcard.2021.04.068 ↗
16. Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction10.1016/j.ahj.2024.10.018 ↗
17. Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Implantation in Patients With Small Aortic Annulus: A Meta-Analysis10.1016/j.amjcard.2023.07.100 ↗
18. Halapas, A., Koliastasis, L., Doundoulakis, I., Antoniou, C.-K., Stefanadis, C., and Tsiachris, D. (2023). Transcatheter Aortic Valve Implantation and Conduction Disturbances: Focus on Clinical Implications. J. Cardiovasc. Dev. Dis., 10.10.3390/jcdd10110469 ↗
19. Impact of Predilation During Transcatheter Aortic Valve Replacement: Insights From the PARTNER 3 Trial10.1161/CIRCINTERVENTIONS.120.010336 ↗
20. Rate and Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation: Current Status10.2174/1573403X15666181205105821 ↗
21. Outcomes and predictors of periprocedural stroke after transcatheter aortic valve implantation10.1016/j.jstrokecerebrovasdis.2023.107054 ↗
22. Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER 2 Randomized Clinical Trial10.1001/jamacardio.2017.2039 ↗
23. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis10.1056/NEJMoa1400590 ↗
24. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients10.1056/NEJMoa1514616 ↗
25. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): A randomised controlled trial10.1016/S0140-6736(15)60308-7 ↗
26. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients10.1016/j.jacc.2018.08.2146 ↗
27. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial10.1093/eurheartj/ehae043 ↗
28. Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial10.1001/jamacardio.2022.2695 ↗
29. Călburean, P.-A., Grebenișan, P., Nistor, I.-A., Pal, K., Vacariu, V., Drincal, R.-K., Ion, A.A., Adorján, I., Oltean, T., and Hadadi, L. (2024). Addition of eptifibatide and manual thrombus aspiration to ticagrelor does not improve long-term survival after STEMI treated with primary PCI. Front. Pharmacol., 15.10.3389/fphar.2024.1415025 ↗
30. High long-term mortality in ischaemic heart disease accentuated among ethnic minorities in Eastern Europe: Findings from a prospective all-comers percutaneous coronary intervention registry in Romania10.1136/jech-2024-222845 ↗
31. Suciu, H., Elkahlout, A., Nicolae, V., Tomșa, F., Stan, A., Al-Hussein, H., Călburean, P.-A., Scurtu, A.-C., Aniței, D.E., and Hadadi, L. (2025). Outcomes and Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with and Without Coronary Artery Disease. J. Cardiovasc. Dev. Dis., 12.10.3390/jcdd12060217 ↗
32. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk10.1161/CIRCULATIONAHA.118.035236 ↗